For the third quarter of FY2026, net sales were 323 million yen, operating loss of 633 million yen, ordinary loss of 628 million yen, and quarterly net loss of 631 million yen. Compared with the same period last year, sales increased significantly while ongoing R&D investments and related expenses weighed on results. Total assets were about 1,997 million yen, net assets were 1,252 million yen. The full-year forecast for this term remains unchanged. Capital policy to be conducted under capital increases from exercise of stock acquisition rights (SARs) is continued.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Clingle Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4884-20260810-01.pdf","jir_short_summary":"For the third quarter of FY2026, net sales were 323 million yen, operating loss of 633 million yen, ordinary loss of 628 million yen, and quarterly net loss of 631 million yen. Compared with the same period last year, sales increased significantly while ongoing R&D investments and related expenses weighed on results. Total assets were about 1,997 million yen, net assets were 1,252 million yen. The full-year forecast for this term remains unchanged. Capital policy to be conducted under capital increases from exercise of stock acquisition rights (SARs) is continued.","jir_summary":"### Overview of operating results\nThis quarter reported net sales of 323 million yen, operating loss of 633 million yen, ordinary loss of 628 million yen, and quarterly net loss of 631 million yen. Compared with the same period last year, sales rose sharply, while continuing drug discovery investments and related expenses remained a weight on profitability. The primary pipeline includes an additional clinical trial for acute spinal cord injury submitted to PMDA in June 2026. The company increased capital through the exercise of stock acquisition rights to strengthen the balance sheet, and plans to continue funding through revenue from active pharmaceutical ingredient (API) supply and joint development agreements.\n\n### Financial position and cash flow movements\nAt the end of the third quarter, current assets stood at 1,958,188 thousand yen, net assets at 1,252,226 thousand yen. Current liabilities were 114,079 thousand yen, non-current liabilities were 630,428 thousand yen, total liabilities were 744,508 thousand yen. The decrease in current assets was due to cash increases from the exercise of SARs and reductions in raw material costs and prepayments. Cash and cash equivalents were 1,695,535 thousand yen. While there is material uncertainty regarding the continuity of the business, financing and expanded partnerships are expected to address this.","jir_financial_highlights":"Net sales: 323,888\u5343\u5186 (YoY +501.0\uff05)\nOperating loss: \u25b3633,948\u5343\u5186 (Improved from \u25b3738,515\u5343\u5186 loss YoY)\nOrdinary loss: \u25b3628,484\u5343\u5186 (Improved from \u25b3738,359\u5343\u5186 YoY)\nQuarterly net loss: \u25b3631,670\u5343\u5186 (Improved from \u25b3739,481\u5343\u5186 YoY)\nTotal assets: 1,996,735\u5343\u5186 (YoY \u25b382,627\u5343\u5186)\nShareholders' equity: 1,216,637\u5343\u5186 (Capital stock and additional paid-in capital increased due to SAR exercise; retained earnings changed by \u25b32,304,379\u5343\u5186)","jir_category":"","jir_hashtags":"#ClinglePharma, #FinancialResults, #CapitalPolicy, #DrugDiscoveryVentures","jir_key_figures":"Net sales: 323,888\u5343\u5186 (YoY +501.0%)\nOperating loss: \u25b3633,948\u5343\u5186\nQuarterly net loss: \u25b3631,670\u5343\u5186","jir_meta_title":"\u3010ClinglePharma\u3011 FY2026\/Q3 Financial Summary\uff5cFundraising and Additional Clinical Trials in Drug Discovery","jir_meta_description":"ClinglePharma FY2026 Q3 Financial Summary. Net sales of 323 million yen (YoY +501%), operating loss of 633 million yen, considerations regarding going concern. Capital strengthened via SAR exercise, with explanation of progress on additional clinical plans.","jir_og_title":"ClinglePharma Q3 Financial Results\uff5cFunding Trends in Drug Discovery","jir_og_description":"ClinglePharma Q3 results. Summary of revenue growth and loss status, and outlook for fundraising and progress of additional clinical trials.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-101677","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n